The three breast cancer cell lines that showed the greatest sensitivity to the HER2-targeted TKIs (SKBR3, BT474, AU-565) have also previously shown significant in vitro trastuzumab sensitivity.36 MDA-MB-453 was the least TKI-responsive HER2+ breast cancer cell line. This evidence concerns the gene ERBB2 and breast cancer.